AR085167A1 - Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit - Google Patents

Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit

Info

Publication number
AR085167A1
AR085167A1 ARP100102836A ARP100102836A AR085167A1 AR 085167 A1 AR085167 A1 AR 085167A1 AR P100102836 A ARP100102836 A AR P100102836A AR P100102836 A ARP100102836 A AR P100102836A AR 085167 A1 AR085167 A1 AR 085167A1
Authority
AR
Argentina
Prior art keywords
polypeptide
gingivalis
seq
identity
variant
Prior art date
Application number
ARP100102836A
Other languages
English (en)
Spanish (es)
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Publication of AR085167A1 publication Critical patent/AR085167A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56955—Bacteria involved in periodontal diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1257—Gram-negative bacteria from Bacteridaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/21—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Pseudomonadaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP100102836A 2009-08-02 2010-08-03 Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit AR085167A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23071709P 2009-08-02 2009-08-02

Publications (1)

Publication Number Publication Date
AR085167A1 true AR085167A1 (es) 2013-09-18

Family

ID=43543841

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102836A AR085167A1 (es) 2009-08-02 2010-08-03 Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit

Country Status (14)

Country Link
US (1) US9366673B2 (enExample)
EP (1) EP2462160A4 (enExample)
JP (2) JP5876411B2 (enExample)
KR (1) KR20120050469A (enExample)
CN (1) CN102712693A (enExample)
AR (1) AR085167A1 (enExample)
AU (1) AU2010281313B2 (enExample)
BR (1) BR112012002429A2 (enExample)
CA (1) CA2769231A1 (enExample)
IL (1) IL217861A0 (enExample)
MX (1) MX2012001495A (enExample)
RU (1) RU2012107993A (enExample)
WO (1) WO2011014947A1 (enExample)
ZA (1) ZA201200799B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2328914B1 (en) 2008-08-29 2017-05-10 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of p.gingivalis infection
MY162557A (en) * 2010-02-26 2017-06-15 Oral Health Australia Pty Ltd Treatment or prevention of infection
CA2894903A1 (en) * 2012-12-14 2014-06-19 Sanofi Pasteur, Ltd. Methods for assessing immunogenicity
WO2016191389A2 (en) * 2015-05-27 2016-12-01 Merial, Inc. Compositions containing antimicrobial igy antibodies, for treatment and prevention of disorders and diseases caused by oral health compromising (ohc) microorganisms
CN111225684A (zh) 2017-10-12 2020-06-02 Sutrovax公司 牙周炎疫苗和相关组合物及使用方法
US12637503B2 (en) 2020-11-03 2026-05-26 K-Bio Investment, Llc Antigen-binding molecules that bind to Porphyromonas gingivalis
US20230204594A1 (en) * 2021-11-17 2023-06-29 Nerd Bio Llc Systems and methods for real-time cellular drug-target engagement
CN114469863B (zh) * 2021-11-26 2023-09-26 南方医科大学南方医院 甾醇脂质体作为牙髓和牙本质药物传递系统的应用
CN116474096A (zh) * 2022-01-14 2023-07-25 中山大学附属口腔医院 靶向牙龈卟啉单胞菌RgpB在结直肠癌的治疗及预防中的应用
EP4514843A1 (en) * 2022-04-26 2025-03-05 K-Bio Investment, LLC Formulation for antigen-binding molecules that bind to porphyromonas gingivalis
JP2025531306A (ja) * 2022-09-16 2025-09-19 シ、シャオジュ ポルフィロモナスジンジバリスに対する抗体及び使用方法
IL325951A (en) 2023-07-19 2026-03-01 Sanofi Sa Porphyromonas gingivalis antigenic constructs
CN116751292B (zh) * 2023-07-31 2024-05-14 河南大学 牙龈卟啉单胞菌Mfa1单克隆抗体及其应用
CN119424610A (zh) * 2024-12-05 2025-02-14 重庆师范大学 具备抗衰老活性的重组蛋白制剂及其制备方法、应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507245A (ja) * 1996-03-22 2000-06-13 ユニバーシティー オブ ジョージア リサーチ ファウンデーション，インコーポレイテッド Ｐｏｒｐｈｙｒｏｍｏｎａｓ ｇｉｎｇｉｖａｌｉｓペプチドを含む免疫原性組成物および方法
AUPN901296A0 (en) * 1996-03-29 1996-04-26 University Of Melbourne, The Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
CA2313823A1 (en) * 1997-12-10 1999-06-17 Csl Limited Porphorymonas gingivalis polypeptides and nucleotides
JP2003192616A (ja) * 2001-12-27 2003-07-09 Univ Nihon 歯周病用ｄｎａワクチン
JP2003286191A (ja) * 2002-03-27 2003-10-07 Univ Nihon 歯周病用粘膜免疫ワクチン
US20070036734A1 (en) * 2003-03-17 2007-02-15 Kirin Beer Kabushiki Kaisha Therapeutic agent for periodontal disease
JP2005179301A (ja) * 2003-12-22 2005-07-07 Univ Nihon 歯周病用経皮免疫ワクチン
CA2652957A1 (en) * 2006-06-27 2008-01-03 Oral Health Australia Pty Ltd. Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease
CN102652831A (zh) * 2007-07-12 2012-09-05 口腔健康澳洲私人有限公司 生物膜的免疫治疗

Also Published As

Publication number Publication date
EP2462160A4 (en) 2013-04-24
RU2012107993A (ru) 2013-09-10
WO2011014947A1 (en) 2011-02-10
US20120156211A1 (en) 2012-06-21
EP2462160A1 (en) 2012-06-13
JP5876411B2 (ja) 2016-03-02
JP2015178533A (ja) 2015-10-08
JP2013501007A (ja) 2013-01-10
AU2010281313A1 (en) 2012-03-08
US9366673B2 (en) 2016-06-14
CN102712693A (zh) 2012-10-03
AU2010281313B2 (en) 2015-09-03
ZA201200799B (en) 2013-06-26
CA2769231A1 (en) 2011-02-10
MX2012001495A (es) 2012-08-03
IL217861A0 (en) 2012-03-29
KR20120050469A (ko) 2012-05-18
BR112012002429A2 (pt) 2016-11-08

Similar Documents

Publication Publication Date Title
ES2542853T3 (es) Método para tratar miastenia grave
ES2540858T3 (es) Composición farmacéutica para el tratamiento y/o la prevención de cáncer
CO6700829A2 (es) Moduladores novedosos y métodos de uso
ES2531115T3 (es) Combinaciones de clados de RrgB neumocócicos
AR083740A1 (es) Anticuerpos dkk1 (dickkopf-1) y metodos de uso
MX358725B (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
PE20171111A1 (es) Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
MX2015004060A (es) 3-epimerasa.
CL2019003404A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico.(divisional solicitud 201702407)
AR072058A1 (es) Composicion detergente que comprende una variante de la familia 44 de xiloglucanasas
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
UY28641A1 (es) Anticuerpos
MX2019008549A (es) Anticuerpos dirigidos a los huesos.
PE20120170A1 (es) Variantes de union a anti-albumina de suero mejoradas
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
CL2017003097A1 (es) Composiciones y métodos para el tratamiento de la enfermedad celiaca
EA201390820A1 (ru) Слитый белок против рака
EP4481045A3 (en) Dna-binding protein using ppr motif, and use thereof
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
RU2012107993A (ru) Полипептиды porhyromonas gingivalis
AR103586A1 (es) Proteínas quiméricas que mejoran la actividad de los dominios de unión a adn y factores de transcripción en plantas
AR119862A1 (es) Polipéptidos mejorados capaces de convertir el sustrato 3-ceto-desoxinivalenol en 3-epi-desoxinivalenol
CL2020002373A1 (es) Composición de vacuna que comprende un péptido aislado de piojo de mar; uso de la vacuna para para prevenir o controlar una infestación de piojos de mar en un salmónido; vector; célula hospedadora (divisional de la solicitud no. 201900422).

Legal Events

Date Code Title Description
FB Suspension of granting procedure